Meeting
2021 ASCO Annual Meeting
Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.
Authors
Leylah Drusbosky
Guardant Health, Inc., Redwood City, CA
Leylah Drusbosky , Mehmet Asim Bilen , Georges Azzi , Pedro C. Barata , Patrick M Boland , Alan Haruo Bryce , Young Kwang Chae , Jeremy Meyer Force , Martin Gutierrez , Pashtoon Murtaza Kasi , Hiba I. Dada , Caroline Weipert , Chuck Hensel , Lesli A. Kiedrowski , Che-Yu Lee , Martina Lefterova , David R. Gandara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3040)
DOI
10.1200/JCO.2021.39.15_suppl.3040
Abstract #
3040
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
First Author: Grant Rauterkus
Poster
2023 ASCO Annual Meeting
The clinical feasibility of circulating tumor DNA alterations in patients with advanced hepatocellular carcinoma.
First Author: Gwangil Kim
Poster
2022 ASCO Quality Care Symposium
Liquid biopsy detection of tumor shed in cancers for which molecular profiling is best practice.
First Author: Pashtoon Murtaza Kasi
